Subconjunctival bevacizumab for iris neovascularisation - Authors' reply

Lancet Diabetes Endocrinol. 2014 Jun;2(6):450-1. doi: 10.1016/S2213-8587(14)70071-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Diabetic Retinopathy / drug therapy*
  • Female
  • Humans
  • Neovascularization, Pathologic / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A